Hemant S. Murthy MD, FACP

Chair- Quality, Mayo Clinic Florida. Hematology/Oncology @MayoCancerCare. BMT/CAR-T, AML/MDS. Tweets opinions are mine. #bmtsm #tcellrx #cartcelltherapy

[Hemant S. Murthy MD, FACP @hemant_murthy]

Honored to be promoted to Professor of Medicine at @MayoClinic. Grateful for the support and belief from friends, colleagues, mentors, teachers and so so many people. Thankful for my family for their continued love and encouragement, allowing me to pursue my career!

[Hemant S. Murthy MD, FACP @hemant_murthy]

@oncology_bg Congratulations and well deserved! 👏

[Hemant S. Murthy MD, FACP @hemant_murthy]

@RahulBanerjeeMD @mtmdphd @fredhutch @UWMedicine Congratulations!

[Premier League @premierleague]

The wait is over.

@Arsenal are Premier League champions.

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

I look forward to this very important presentation in #EHA2026 about value of transplant in TP53 mutated #MDSsm and #AMLsm. The results clearly indicate a tail at end of curve and around 20% 23-year OS even among biallelic TP53mut patients, and especially in those with lower blast counts. Do NOT deprive patients from the opportunity of transplant without a very well-informed discussion!

Patients with KPS >80 had an estimated 3-year OS of 49.3%, compared with 30.2% for KPS ≤80. Biallelic TP53 was associated with inferior survival (HR 4.05, 95% CI 1.76–9.32; p=0.001) (figure 1b), reaching statistical significance only in the MDS subgroup. A low blast count at diagnosis was associated with improved survival (HR 0.50, 95% CI 0.29–0.88; p=0.02).

No clear associations were observed for age, HCT-CI, donor type, conditioning intensity or ATG. NRM did not differ significantly between MDS and AML (figure 1c).

ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD... - Myhre A - EHA-6995 - Jun 13 2026

[Vincent Rajkumar @VincentRK]

We need influential medical experts to be active here on X. We can help by providing good medical information and updates for patients and colleagues. We can network. We can counter misinformation. Clarify complex questions. Share accomplishments and publications. And more. I learn every day.

Although X has is not the same as the amazing platform Twitter used to be, it’s still the Number one social media platform for medicine. I’m happy to be here.

[Vincent Rajkumar @VincentRK]

Clinical trials:
Easy to criticize. Hard to do.

[Straight Florida @StraightFlorida]

Florida Man doesn’t ask for permission.
He just straps on a jet-propelled hoverboard, hooks up his dog to a jet ski, and goes for a Sunday cruise like it’s completely normal.

This is why the rest of the country will never understand us.
Peak Florida. Never change.

[Mario Nawfal @MarioNawfal]

🇯🇵A Japanese developer built an app that puts a fat cat on your screen and forces you to take a break

Silicon Valley spent billions on wellness platforms, mindfulness subscriptions, and digital detox retreats

A guy in Japan said: fat cat, problem solved

[Hemant S. Murthy MD, FACP @hemant_murthy]

@nihardesai89 @Haemophage @GonzaloBentoli1 @KFHemeOnc @amjimenezmd @sghmd Assuming both pbsc grafts. I prefer C mismatch unrelated

[Hemant S. Murthy MD, FACP @hemant_murthy]

@LeukDocJZ @UNC_SOM @UNC_Lineberger @hopkinskimmel Congratulations @LeukDocJZ 👏

[Hemant S. Murthy MD, FACP @hemant_murthy]

Congratulations @Ernesto55788765 @edwardziga and team for ground breaking work for patients with #sicklecell disease. Phase 1/2 trial of risto-cel in patients with SCD led to rapid robust increase HbF,reduced HbS & no VOc @MayoClinic @MayoCancerCare @MKD_BMT @VamsiVelcheti

[NEJM @NEJM]

In the BEACON study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. Full study results: https://t.co/fdrUyAa6Ta

Editorial: More Options for Gene Editing in Hemoglobinopathies https://t.co/8amzRCFE0G

Further reading:
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease (RUBY study) https://t.co/d0rIzzotFU
📄 Original Article: CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia (EdiThal study) https://t.co/rZUvlLzAvL

[Hemant S. Murthy MD, FACP @hemant_murthy]

@DrRoyHerbst @EladSharonMD @DartmouthCancer @GeiselMed Congratulations!

[Gianrico Farrugia @GFarrugiaMD]

A new study evaluating Mayo’s Cancer CARE Beyond Walls program highlights how home-based chemotherapy can reduce the burden of cancer treatment while improving patients’ quality of life.
https://t.co/AA38ASuEsJ

[GvHD Hub @gvhd_hub]

CONGRESS | #EBMT26 | PRESENTATION

A Samer Al-Homsi presents interim results from the phase I-IIb ABC trial, evaluating PTCy dose reduction in patients receiving calcineurin- and mTOR inhibitor-free #GvHD prophylaxis with PTCy + bortezomib + abatacept (N = 60). PTCy dose was reduced from 50 mg/kg to 37.5 mg/kg. Reduced-dose vs full-dose PTCy was associated with faster neutrophil and platelet engraftment (15 vs 17 days; p = 0.004 and 22 vs 25.5 days; p = 0.04, respectively). No primary or secondary graft failure occurred. There were no differences in CD3+, CD4+ or CD8+ cell recovery between the two PTCy groups. By Day +180, the estimated cumulative incidences of Grade II-IV #aGvHD were 4.0% with full-dose PTCy and 11.8% with reduced-dose PTCy (p = 0.29). The 1-year estimated cumulative incidences of moderate and severe #cGvHD were 12% and 9.5% with full- and reduced-dose PTCy, respectively (p = 0.87). At 1 year, OS and GRFS were 91.3% and 70.9%, respectively.

Follow our live feed for more updates: https://t.co/zjpTpxhAZk

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#GvHDsm #MedNews #MedEd @TheEBMT @ASamerAlHomsi1 @ZuckerSoM

[Hemant S. Murthy MD, FACP @hemant_murthy]

@ndmom Congratulations!! 🎉👏

[Hemant S. Murthy MD, FACP @hemant_murthy]

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls — Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy https://t.co/PULo29DDCH @RDroncaDr @CherylWillmanMD @KentThielen @Jcj84Jeremy @DoctorQMd @MayoClinic @MayoCancerCare

[Hemant S. Murthy MD, FACP @hemant_murthy]

@chadinabhan @premierleague @ManUtd

[ASSFN @ASSFNeurosurg]

We grieve the untimely and heartbreaking loss of Dr. Sanjeet Grewal — a beloved husband, father, son, friend and an exceptionally gifted stereotactic and functional neurosurgeon.

Read more: https://t.co/0JB2cXP4qW

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

📣🚨Announcing the:

⭐️ 35th ANNUAL @MayoCancerCare Florida #Hematology/#Oncology Reviews at Amelia Island #RitzCarlton, I’m honored to co-lead from Jul 30 to Aug 1, 2026.

✅Comprehensive #CME #Practical (in-person & virtual) Conference, with AMAZING speakers from @MayoClinic & other GREAT centers.

Join us👇🏼
https://t.co/pJe4yZIWRf

[Yi Lin @YiLinMDPhD]

Come to the Plasma Cell Disorder Working committee this afternoon #Tandem2026 @CIBMTR  to vote on proposals! @ZanwarSaurabh @nadineabdal Ken Lim propose to examine comparative effectiveness of early vs late #CART in #mmsm 🧬📊@MayoCancerCare
 #medtwitter